Science and Development Network
News, views and information about science, technology and the developing world
Source: International Herald Tribune
8 June 2007 | EN | 中文
Mass treatment could wipe out malaria
CDC
A group of Chinese researchers say we already have the weapon to defeat malaria but it is being used in the wrong way, writes David Lague in the International Herald Tribune.
The team want to trial giving artemisinin combined with another drug as a mass treatment to 40,000 people on Moheli Island off the east coast of Africa, where the disease is endemic.
They say giving everyone two doses of the drugs, 40 days apart — rather than the current practice of dispensing them numerous times a year — would clear the parasite from human and mosquito populations for an extended period.
The therapy would knock the parasite out of the human population and in the meantime, all malaria-carrying mosquitoes would die, as their lifespan is only 30 days.
Since the malaria parasite only lives in people and female mosquitoes, they say that this would dramatically reduce transmission of the parasite, which could eventually be controlled at a low level.
Some think this is a risky plan: simultaneous mass treatment, without the means to control malaria-carrying mosquitoes, could increase resistance to artemisinin.
However, the World Health Organization has offered support to the Chinese government-funded project, and earlier work in Cambodia yielded encouraging results.
The trial could begin within three months.
Our blog, by SciDev.Net columnist Priya Shetty, will fill you in, as will our interview with the Global Forum's Gill Samuels
Will USAID’s likely new chief switch the focus from shipping food to growing it?
Policymakers must improve water storage to help developing countries adapt to climate change
Add your comment
All comments are subject to approval and we reserve the right to edit comments containing inappropriate/unsuitable language. SciDev.Net holds copyright for all material posted on the website. Please see terms of use for further details.
You need to be signed in to post a comment or to email a consenting comment author. Please sign in or sign up.